Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Paired Laboratory Tests Predict Vein Graft Occlusion

By LabMedica International staff writers
Posted on 15 Mar 2011
A blood test for platelet clumping velocity and another for a clumping chemical byproduct can predict whether coronary artery bypass grafting will be successful.

The aggregation of platelets and their activation in plasma and blood can be assessed and correlated with the levels of a chemical found in the urine to saphenous vein graft (SVG) occlusion.

A team of cardiologists at Johns Hopkins School of Medicine, (Baltimore, MD, USA), examined platelet activation 3 days and 6 months after coronary artery bypass graft surgery in 229 subjects receiving aspirin monotherapy.

The cardiologists used a platelet function analyzer (PFA), and measured closure time (CT) using collagen/epinephrine agonist cartridge and collagen/adenosine diphosphate (CADP) agonist cartridge (Accumetrics, Inc., San Diego, CA, USA). Thromboxane A2 (TXA2) generation was quantified by measuring the concentration of its stable metabolite 11-dehydro-thromboxane B2 (UTXB2) in urine by enzyme-linked immunosorbent assay (ELISA) and expressed as a ratio to urinary creatinine.

The results from the Platelet Function Analyzer-100 (PFA-100; Siemens Healthcare Diagnostics, Newark, DE, USA), showed that those who ranked in the quarter with the slowest blood-clotting times had an 11% vein graft failure rate, while those whose blood clotted fastest had a 28% risk. Tests for UTXB, a highly reactive chemical whose action is normally suppressed by aspirin, were equally linked to vein graft failure. Study participants in the quartile with the lowest amounts of UTXB had a 12% likelihood of one or more veins occluding, while in the quartile with the highest amounts of UTXB, the rate was 29%. When results of both tests were combined, patients with the "most-sticky" platelets and highest UTXB levels had a nearly sevenfold increased risk of vein graft failure, compared to those who had the "least-sticky" platelets and lowest UTXB levels.

Jeffrey Rade, MD, the senior investigator, said, "These two tests offer physicians new tools for early detection of bypass patients at greatest risk of vein graft failure, giving them advance warning and, potentially, buying time to try drug or surgical therapies that might either slow down or reverse the narrowing and buildup of plaque and dead cells inside the grafted vein".

The authors concluded that aspirin-insensitive thromboxane generation measured by UTXB2 and shear-dependent platelet hyper-reactivity measured by Platelet Function Analyzer-100 CADP CT are novel independent risk factors for early SVG thrombosis after coronary artery bypass graft surgery. The study was published March 1, 2011, in the Journal of the American College of Cardiology.


Related Links:

Johns Hopkins School of Medicine
Accumetrics, Inc.
Siemens Healthcare Diagnostics



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.